Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2011 Jan;26(1):59-66.
doi: 10.3346/jkms.2011.26.1.59. Epub 2010 Dec 22.

Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis

Ho Jun Chin  1 , Se Won Oh, Ho Suk Goo, Jieun Oh, Jung Woo Noh, Jong Tae Cho, Ki Young Na, Suhnggwon Kim, Dong-Wan Chae; Members of The PREMIER Group
Collaborators, Affiliations
Comparative Study

Effect of RAAS inhibition on the incidence of cancer and cancer mortality in patients with glomerulonephritis

Ho Jun Chin et al. J Korean Med Sci. 2011 Jan.

Abstract

Angiotensin II type 1 receptor blocker (ARB), which is frequently prescribed in patients with glomerulonephritis (GN), is suggested to increase the risk of cancer. We registered 3,288 patients with renal biopsy and analyzed the relationship between the use of renin-angiotensin-aldosterone system (RAAS) blockade and the incidence of cancer or cancer mortality. After renal biopsy, cancer developed in 33 patients with an incidence rate of 1.0% (95% of CI for incidence: 0.7%-1.3%). There was no difference in the cancer incidence among the groups according to the use of angiotensin-converting enzyme inhibitors (ACEI) or ARB: 1.2% in the None (23/1960), 0.7% in the ARB-only (5/748), 0.4% in the ACEI-only (1/247), and 1.2% in the ACEI-ARB (4/333) (P = 0.487) groups. The cancer mortality was 2.1%, 0.4%, 0.0%, and 0.3% in None, ACEI-only, ARB-only, and ACEI-ARB group, respectively (P < 0.001). The risk of cancer mortality in patients with ARB was only 0.124 (0.034-0.445) compared to that of non-users of ARB by Cox's hazard proportional analysis. In conclusion, prescription of ACEI or ARB in patients with GN does not increase cancer incidence and recipients of ARB show rather lower rates of all-cause mortality and cancer mortality.

Keywords: Angiotensin II Type 1 Receptor Blockers; Glomerulonephritis; Neoplasms.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The incidence of cancer and cancer mortality after kidney biopsy. (A) Incidence of cancer, (B) Incidence of cancer mortality. There was no difference between None and other three groups in cancer incidence, also (P = 0.568). The cancer mortality in None group was higher than other 3 groups, too (P < 0.001).
See this image and copyright information in PMC

References

    1. 2009 annual data report. Chapter 12. International Comparison. Unites States Renal Data System. [accessed on 5 Sep 2010]. pp. 343–354. Available at http://www.usrds.org/2009/pdf/V2_12_09.PDF.
    1. Cameron JS. The long-term outcome of glomerular disease. In: Schrier RW, Gottschalk CW, editors. Disease of the Kidney. Boston, MA: Little, Brown; 1988. pp. 2127–2189.
    1. Simon P, Ramée MP, Ang KS, Cam G. Variations of primary glomerulonephritis incidence in a rural area of 400,000 inhabitants in the last decade. Nephron. 1987;45:171. - PubMed
    1. Briganti EM, Dowling J, Finlay M, Hill PA, Jones CL, Kincaid-Smith PS, Sinclair R, McNeil JJ, Atkins RC. The incidence of biopsy-proven glomerulonephritis in Australia. Nephrol Dial Transplant. 2001;16:1364–1367. - PubMed
    1. Heaf J, Løkkegaard H, Larsen S. The epidemiology and prognosis of glomerulonephritis in Denmark 1985-1997. Nephrol Dial Transplant. 1999;14:1889–1897. - PubMed

Publication types

MeSH terms

Substances